FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT01418222. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.
Study identification
- NCT ID
- NCT01418222
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 194 participants
Conditions and interventions
Conditions
Interventions
- 5-FU Drug
- FOLFOX regimen Drug
- Placebo Drug
- bevacizumab [Avastin] Drug
- leucovorin Drug
- onartuzumab [MetMAb] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2011 (Actual)
- Primary completion
- Mar 18, 2013 (Actual)
- Completion
- Mar 18, 2013 (Actual)
- Last update posted
- May 30, 2017
2011 – 2013
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Almac Clinical Technologies | San Francisco | California | 94105 | — |
| Rocky Mountain Cancer Centers; Bone and Marrow Trans | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists; SCRI | Fort Myers | Florida | 33901 | — |
| Florida Hospital Cancer Inst | Orlando | Florida | 32804 | — |
| Georgia Cancer Specialists - Northside | Atlanta | Georgia | 30341 | — |
| University of Chicago; Hematology/Oncology | Chicago | Illinois | 60637 | — |
| Ingalls Cancer Research Center | Harvey | Illinois | 60426 | — |
| Ingalls Memorial Hospital; Cancer Research Center | Harvey | Illinois | 60426 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Center For Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Saint Louis Cancer Care, LLP | Bridgeton | Missouri | 63044 | — |
| Research Medical Center - Antibiotic Research Associates, Inc. | Kansas City | Missouri | 64132 | — |
| Hem-Onc Assoc of Northern NJ | Morristown | New Jersey | 07960 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Toledo Comm. Onc. Program | Toledo | Ohio | 43623 | — |
| University of Oklahoma; Stephenson Oklahoma Canc Ctr | Oklahoma City | Oklahoma | 73104 | — |
| South Carolina Oncology Associates - SCRI | Columbia | South Carolina | 29210 | — |
| Spartanburg Regional Medical Center | Spartanburg | South Carolina | 29303 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Onc., PLLC - SCRI | Nashville | Tennessee | 37203 | — |
| Ctr for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| South Texas Oncology & Hematology, P.A. | San Antonio | Texas | 78229 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01418222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01418222 live on ClinicalTrials.gov.